The adjustment in price target by Morgan Stanley reflects a slight change in valuation expectations for Biomarin Pharmaceutical. While the Overweight rating indicates continued confidence in the company's prospects, the reduction in price target suggests a recalibration of short-term price expectations. This could lead to a neutral short-term impact on the stock as the market digests the revised target alongside the maintained positive outlook.